Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Bristol Myers Squibb's robust pipeline and strong balance sheet support future growth and income potential. Find out what ...

That could happen by Dec. 29, when the FDA is expected to issue a verdict on an Opdivo formulation administered via an under-the-skin injection. Subcutaneous Opdivo is the product of a partnership ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...

September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...

BMS Proposes Perioperative Opdivo Regimen in NSCLC Bristol Myers Squibb is advancing ... Zealand is developing the drug candidate as a subcutaneous continuous infusion delivered via a wearable pump ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market entry ...

Opdivo carries a very high cost in the US – $12,500 a month or $150,000 for patients who stay on the drug for a year, but BMS is likely to offer the drug at a discount on this level in Europe ...

The company recently received positive news with the FDA moving up the PDUFA date for subcutaneous Opdivo to December 2024, two months earlier than previously expected. Analysts anticipate ...

Among patients with advanced melanoma, treatment with Opdivo (nivolumab) with or without Yervoy (ipilimumab) benefited both overall survival (OS, the time a patient lives, regardless of disease status ...

The agency has already approved Keytruda and Opdivo when combined with chemotherapy as a first-line treatment for patients with HER2-negative unresectable or metastatic gastric or gastroesophageal ...